Antiviral Activity Of Bacillus Sp. Isolated From The Marine Sponge Petromica Citrina Against Bovine Viral Diarrhea Virus, A Surrogate Model Of The Hepatitis C Virus

The Hepatitis C virus causes chronic infections in humans, which can develop to liver cirrhosis and hepatocellular carcinoma. The Bovine viral diarrhea virus is used as a surrogate model for antiviral assays for the HCV. From marine invertebrates and microorganisms isolated from them, extracts were prepared for assessment of their possible antiviral activity. Of the 128 tested, 2 were considered active and 1 was considered promising. The best result was obtained from the extracts produced from the Bacillus sp. isolated from the sponge Petromica citrina. The extracts 555 (500 μg/mL, SI>18) and 584 (150 μg/mL, SI 27) showed a percentage of protection of 98% against BVDV, and the extract 616, 90% of protection. All of them showed activity during the viral adsorption. Thus, various substances are active on these studied organisms and may lead to the development of drugs which ensure an alternative therapy for the treatment of hepatitis C. © 2013 by the authors; licensee MDPI, Basel, Switzerland.5512191230Yasuhara-Bell, J., Yang, Y., Barlow, R., Trapido-Rosental, H., Lu, Y., In vitro evaluation of marine microorganism extracts for antiviral activity (2010) Virol. J., 7, p. 182Ravikumar, Y.S., Upasana, R., Nandhitha, M., Perween, A., Naika, H.R., Inhibition of hepatitis C virus replication by herbal extract: Phyllanthus amarus as a potent natural source (2011) Virus Res., 158, pp. 89-97Li, H., Stoddard, M.B., Wang, S., Blair, L.M., Giorgi, E.E., Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome sequencing (2012) PLoS Pathog., 8, pp. e1002880Suzuki, T., Ishii, K., Aizaki, H., Wakita, T., Hepatitis C viral life cycle (2007) Adv. Drug Del. Rev., 59, pp. 1200-1212Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Klenerman, P., Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man (2012) SciTransl Med., 4, pp. 115ra1. , doi:10.1126/scitranslmed.3003155Sako, K., Aoyama, H., Sato, S., Hashimoto, Y., Baba, M., γ-Carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity (2008) Bioorg. Med. Chem., 16, pp. 3780-3790Martinot-Peignoux, M., Boyer, N., Pouteau, M., Castelnau, C., Giuily, N., Duchatelle, V., Aupérin, A., Erlinger, S., Predictors of sustained response to alpha interferon therapy in chronic hepatitis C (1998) J. Hepatol., 29, pp. 214-223Lemon, S.M., McKeating, J.A., Pietschmann, T., Frick, D.N., Glenn, J.S., Tellinghuisen, T.L., Symons, J., Furman, P.A., Development of novel therapies for hepatitis C (2010) Antiviral Res., 86, pp. 79-92Duverlie, G., Wychowski, C., Cell culture systems for the hepatitis C virus (2007) J. Gastroenterol., 13, pp. 2442-2445Finkielsztein, L.M., Moltrasio, G.Y., Caputto, M.E., Castro, E.F., Cavallaro, L.V., Moglioni, A.G., What is known about the antiviral agents active against bovine viral diarrhea virus (BVDV)? (2010) Curr. Med. Chem., 17, pp. 2933-2955Buckwold, V.E., Beer, B.E., Donis, R.O., Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents (2003) Antiviral Res., 60, pp. 1-15Zitzmann, N., Mehta, A.S., Carrouee, S., Butters, T.D., Platt, F.M., McCauley, J., Blumberg, B.S., Block, T.M., Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a Pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents (1999) Proc. Natl. Acad. Sci., 96, pp. 11878-11882Baginski, S.G., Pevear, D.C., Seipel, M., Sun, S.C., Benetatos, C.A., Chunduru, S.K., Rice, C.M., Collett, M.S., Mechanism of action of a pestivirus antiviral compound (2000) Proc. Natl. Acad. Sci., 97, pp. 7981-7986Buckwold, V.E., Wei, J., Wenzel-Mathers, M., Russell, J., Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication (2003) Antimicrobial. Agents Chemother., 47, pp. 2293-2298Yanagida, K., Baba, C., Baba, M., Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: Synergistic effect of combination with interferon-α (2004) Antiviral Res., 64, pp. 195-201Mosmann, T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays (1983) J. Immun. Meth., 65, pp. 55-63Scudiero, D.A., Shoemaker, R.H., Paull, K.D., Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines (1988) Cancer Res., 48, pp. 4827-4833Reed, L.J., Münch, H.A., A simple method of estimating fifty percent endpoints (1938) Am. J. Hyg., 27, pp. 493-497Takeuchi, H., Baba, M., Shigeta, S., An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds (1991) J. Virol. Methods., 33, pp. 61-71Koseki, I., Simoni, I.C., Nakamura, I.T., Noronha, A.B., Costa, S.S., Antiviral activity of plant extracts against aphtovirus, pseudorabiesvírus and pestivirus in cell cultures (1990) Microbios. Letters., 44, pp. 19-30Pospiech, A., Neumann, B., A versatile quick-prep of genomic DNA from Gram-positive bacteria (1995) Trends Genetics, 11, pp. 217-218Lane, D.J., Pace, B., Olsen, G.J., Stahl, D.A., Sogin, M.L., Pace, N.R., Rapid determination of 16S ribosomal RNA sequences for phylogenetic analysis (1985) Proc. Nat. Acad. Sci., 82, pp. 6955-6959Menezes, C.B.A., Bonugli-Santos, R.C., Miqueletto, P.B., Passarini, M.R.Z., Silva, C.H.D., Justo, M.R., Rebeca, R., Sette, L.D., Microbial diversity associated with algae, ascidians and sponges from the north coast of São Paulo state, Brazil (2010) Microbiol. Res., 165, pp. 466-482Costa-Lotufo, L.V., Wilke, D.V., Jimenez, P.C., Epifanio, R.A., Organismos marinhos como fonte de novos fármacos: Histórico & perspectivas (2009) Quim. Nova., 32, pp. 703-716Laport, M.S., Santos, O.C., Muricy, G., Marine sponges: Potential sources of new antimicrobial drugs (2009) Curr. Pharm. Biotechnol., 10, pp. 86-105Marinho, P.R., Muricy, G.R.S., Silva, M.F.L., de Marval, M.G., Laport, M.S., Antibiotic-resistant bacteria inhibited by extracts and fractions from Brazilian marine sponges (2010) Brazilian J. Pharmac., 20, pp. 267-275Donadio, S., Monciardini, P., Sosio, M., Polyketide synthases and nonribosomal peptide synthetases: The emerging view from bacterial genomics (2007) Nat. Prod. Rep., 24, pp. 1073-1109Mikhaǐlova, N.A., Nagieva, F.G., Grin'ko, O.M., Zverev, V.V., Experimental study of antiviral activity of spore-forming bacterium Bacillus pumilus "Pashkov" (2010) Mikrobiol. Epidemiol. Immunobiol., 2, pp. 69-74Gribencha, S.V., Potselueva, L.A., Barinskiǐ, I.F., Deev, S.M., Balandin, T.G., Leshchinskaia, I.B., Antiviral activity of Bacillus intermedius RNAase in guinea-pigs and rabbits infected with outdoor rabies virus (2006) Vopr. Virusol., 51, pp. 41-43Gribencha, S.V., Potselueva, L.A., Barinskiǐ, I.F., Balandin, T.G., Deev, S.M., Leshchinskaia, I.B., The antiviral activity of RNAse Bacillus intermedius in experiments with mice preinfected with street rabies virus (2004) Vopr. Virusol., 49, pp. 38-41Zhou, W.W., Niu, T.G., Purification and some properties of an extracellular ribonuclease with antiviral activity against tobacco mosaic virus from Bacillus cereus (2009) Biotechnol. Lett., 31, pp. 101-105Boya, C.A., Herrera, L., Guzman, H.M., Gutierrez, M., Antiplasmodial activity of bacilosarcinA isolated from the octocoral-associated bacterium Bacillus sp. collected in Panama (2012) J. Pharm. Bioallied. Sci., 4, pp. 66-69El-Sersy, N.A., Abdelwahab, A.E., Abouelkhiir, S.S., Antibacterial and anticancer activity of ε-poly-L-lysine (ε-PL) produced by a marine Bacillus subtilis sp (2012) J. Basic Microbiol., 52, pp. 513-522Craczyc, K., Trojanowska, K., Mueller, A., Antifungal activity of Bacillus coagulans against Fusarium sp (2002) Acta Microbiol. Pol., 51, pp. 275-283Sohn, M.J., Zheng, C.J., Kim, W.G., Macrolactin S, a new antibacterial agent with FabG-inhibitory activity from Bacillus sp. AT28 (2008) J. Antibiot., 61, pp. 687-691Moshafi, M.H., Forootanfar, H., Ameri, A., Antimicrobial activity of Bacillus sp. strain FAS1 isolated from soil. Pak (2011) J. Pharm. Sci., 24, pp. 269-27

Supplement: "Localization and broadband follow-up of the gravitational-wave transient GW150914" (2016, ApJL, 826, L13)

This Supplement provides supporting material for Abbott et al. (2016a). We briefly summarize past electromagnetic (EM) follow-up efforts as well as the organization and policy of the current EM follow-up program. We compare the four probability sky maps produced for the gravitational-wave transient GW150914, and provide additional details of the EM follow-up observations that were performed in the different bands

Multi-messenger observations of a binary neutron star merger

On 2017 August 17 a binary neutron star coalescence candidate (later designated GW170817) with merger time 12:41:04 UTC was observed through gravitational waves by the Advanced LIGO and Advanced Virgo detectors. The Fermi Gamma-ray Burst Monitor independently detected a gamma-ray burst (GRB 170817A) with a time delay of ~1.7 s with respect to the merger time. From the gravitational-wave signal, the source was initially localized to a sky region of 31 deg2 at a luminosity distance of 40+8-8 Mpc and with component masses consistent with neutron stars. The component masses were later measured to be in the range 0.86 to 2.26 Mo. An extensive observing campaign was launched across the electromagnetic spectrum leading to the discovery of a bright optical transient (SSS17a, now with the IAU identification of AT 2017gfo) in NGC 4993 (at ~40 Mpc) less than 11 hours after the merger by the One- Meter, Two Hemisphere (1M2H) team using the 1 m Swope Telescope. The optical transient was independently detected by multiple teams within an hour. Subsequent observations targeted the object and its environment. Early ultraviolet observations revealed a blue transient that faded within 48 hours. Optical and infrared observations showed a redward evolution over ~10 days. Following early non-detections, X-ray and radio emission were discovered at the transient’s position ~9 and ~16 days, respectively, after the merger. Both the X-ray and radio emission likely arise from a physical process that is distinct from the one that generates the UV/optical/near-infrared emission. No ultra-high-energy gamma-rays and no neutrino candidates consistent with the source were found in follow-up searches. These observations support the hypothesis that GW170817 was produced by the merger of two neutron stars in NGC4993 followed by a short gamma-ray burst (GRB 170817A) and a kilonova/macronova powered by the radioactive decay of r-process nuclei synthesized in the ejecta

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Localization and broadband follow-up of the gravitational-wave transient GW150914

A gravitational-wave (GW) transient was identified in data recorded by the Advanced Laser Interferometer Gravitational-wave Observatory (LIGO) detectors on 2015 September 14. The event, initially designated G184098 and later given the name GW150914, is described in detail elsewhere. By prior arrangement, preliminary estimates of the time, significance, and sky location of the event were shared with 63 teams of observers covering radio, optical, near-infrared, X-ray, and gamma-ray wavelengths with ground- and space-based facilities. In this Letter we describe the low-latency analysis of the GW data and present the sky localization of the first observed compact binary merger. We summarize the follow-up observations reported by 25 teams via private Gamma-ray Coordinates Network circulars, giving an overview of the participating facilities, the GW sky localization coverage, the timeline, and depth of the observations. As this event turned out to be a binary black hole merger, there is little expectation of a detectable electromagnetic (EM) signature. Nevertheless, this first broadband campaign to search for a counterpart of an Advanced LIGO source represents a milestone and highlights the broad capabilities of the transient astronomy community and the observing strategies that have been developed to pursue neutron star binary merger events. Detailed investigations of the EM data and results of the EM follow-up campaign are being disseminated in papers by the individual teams

Localization and Broadband Follow-up of the Gravitational-wave Transient GW150914

A gravitational-wave (GW) transient was identified in data recorded by the Advanced Laser Interferometer Gravitational-wave Observatory (LIGO) detectors on 2015 September 14. The event, initially designated G184098 and later given the name GW150914, is described in detail elsewhere. By prior arrangement, preliminary estimates of the time, significance, and sky location of the event were shared with 63 teams of observers covering radio, optical, near-infrared, X-ray, and gamma-ray wavelengths with ground- and space-based facilities. In this Letter we describe the low-latency analysis of the GW data and present the sky localization of the first observed compact binary merger. We summarize the follow-up observations reported by 25 teams via private Gamma-ray Coordinates Network circulars, giving an overview of the participating facilities, the GW sky localization coverage, the timeline, and depth of the observations. As this event turned out to be a binary black hole merger, there is little expectation of a detectable electromagnetic (EM) signature. Nevertheless, this first broadband campaign to search for a counterpart of an Advanced LIGO source represents a milestone and highlights the broad capabilities of the transient astronomy community and the observing strategies that have been developed to pursue neutron star binary merger events. Detailed investigations of the EM data and results of the EM follow-up campaign are being disseminated in papers by the individual teams. </p

Localization and broadband follow-up of the gravitational-wave transient GW150914

A gravitational-wave transient was identified in data recorded by the Advanced LIGO detectors on 2015 September 14. The event candidate, initially designated G184098 and later given the name GW150914, is described in detail elsewhere. By prior arrangement, preliminary estimates of the time, significance, and sky location of the event were shared with 63 teams of observers covering radio, optical, near-infrared, X-ray, and gamma-ray wavelengths with ground- and space-based facilities. In this Letter we describe the low-latency analysis of the gravitational wave data and present the sky localization of the first observed compact binary merger. We summarize the follow-up observations reported by 25 teams via private Gamma-ray Coordinates Network Circulars, giving an overview of the participating facilities, the gravitational wave sky localization coverage, the timeline and depth of the observations. As this event turned out to be a binary black hole merger, there is little expectation of a detectable electromagnetic signature. Nevertheless, this first broadband campaign to search for a counterpart of an Advanced LIGO source represents a milestone and highlights the broad capabilities of the transient astronomy community and the observing strategies that have been developed to pursue neutron star binary merger events. Detailed investigations of the electromagnetic data and results of the electromagnetic follow-up campaign will be disseminated in the papers of the individual teams